A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Nave Mantle Cell Lymphoma (BRUIN MCL-321)
Study of LOXO-305 in Patients with Mantle Cell Lymphoma (MCL)
Sponsor: Loxo Oncology, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAT6851
U.S. Govt. ID: NCT04662255
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This research study is being done to test the effectiveness and safety of an investigational treatment called LOXO-305. LOXO-305 is an investigational (or experimental) drug that may treat certain cancers like leukemia and lymphomas, including, mantle cell lymphoma (MCL). These cancers are dependent on or addicted to a protein made by the cancers called BTK. LOXO-305 is a BTK inhibitorit is designed to block both normal and mutated forms of BTK in these cancers.
Investigator
Andrew Lipsky, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Are you able to swallow oral study medication? Yes No
Have you had major surgery within 4 weeks prior to study? Yes No
Is your life expectancy greater than 3 months? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162